Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7303
    +0.0005 (+0.07%)
     

  • CRUDE OIL

    82.86
    +0.05 (+0.06%)
     

  • Bitcoin CAD

    88,049.85
    -3,122.61 (-3.42%)
     

  • CMC Crypto 200

    1,391.90
    -32.20 (-2.26%)
     

  • GOLD FUTURES

    2,324.80
    -13.60 (-0.58%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,459.00
    -205.50 (-1.16%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,724.59
    -735.49 (-1.91%)
     

  • CAD/EUR

    0.6819
    0.0000 (0.00%)
     

Seagen loses arbitration against Daiichi Sankyo over drug technology

Reuters
Updated ·1 min read
Illustration shows test tubes and Seagen logo

(Reuters) -U.S. drugmaker Seagen Inc said on Friday an arbitrator had ruled in favor of Japan's Daiichi Sankyo over an agreement between the two companies for using its drug technology.

The companies have been locked in a legal battle over patents on Daiichi and AstraZeneca Plc's breast-cancer drug Enhertu, which Seagen says violates its patents.

Seagen filed an arbitration demand in 2019, saying the technology used in Enhertu are improvements to its antibody-drug conjugate technology.

The company, which was reported to be an acquisition target for Merck & Co Inc, said the ownership of the technology was assigned to it under a 2008 agreement with Daiichi Sankyo.

ADVERTISEMENT

In the patent fight, a Texas jury had in April awarded Seagen nearly $42 million from Daiichi Sankyo.

Shares of Seagen were down 2.4% at $169.89 in afternoon trading.

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)